StreetInsider.com News Articles

Form SCHEDULE 13G/A Crinetics Pharmaceutical Filed by: FMR LLC

Fri, 07 Aug 2026 11:05:00 -0400

si-local-file:///var/storage/secattach/20260807/26889281.html

Form SCHEDULE 13G/A Crinetics Pharmaceutical Filed by: FMR LLC

Fri, 07 Aug 2026 11:05:00 -0400

si-local-file:///var/storage/secattach/20260807/26889281.html

Crinetics Pharmaceuticals (CRNX) Tops Q2 EPS by 8c

Mon, 03 Aug 2026 16:43:45 -0400

Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q2 EPS of ($1.14), $0.08 better than the analyst estimate of ($1.22). Revenue for the quarter came in at $25.12 million versus the consensus estimate of $14.87 million.

For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.

Form 10-Q Crinetics Pharmaceutical For: Jun 30

Mon, 03 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260803/26857968.html

Form 10-Q Crinetics Pharmaceutical For: Jun 30

Mon, 03 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260803/26857968.html

Form 8-K Crinetics Pharmaceutical For: Aug 03

Mon, 03 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260803/26857871.html

Form 8-K Crinetics Pharmaceutical For: Aug 03

Mon, 03 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260803/26857871.html

Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Mon, 03 Aug 2026 16:05:00 -0400

Announced Vertex Agreement to Acquire Crinetics for Total Equity Value of Approximately $10.0 Billion, or Approximately $8.8B Net of Estimated Cash Acquired

PALSONIFY® (Paltusotine) Net Product Revenue of $24.0 Million for Second-Quarter 2026

SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today reported financial results for the second quarter ended June

Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Mon, 03 Aug 2026 16:05:00 -0400

Announced Vertex Agreement to Acquire Crinetics for Total Equity Value of Approximately $10.0 Billion, or Approximately $8.8B Net of Estimated Cash Acquired

PALSONIFY® (Paltusotine) Net Product Revenue of $24.0 Million for Second-Quarter 2026

Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Mon, 03 Aug 2026 16:05:00 -0400

Announced Vertex Agreement to Acquire Crinetics for Total Equity Value of Approximately $10.0 Billion, or Approximately $8.8B Net of Estimated Cash Acquired

PALSONIFY® (Paltusotine) Net Product Revenue of $24.0 Million for Second-Quarter 2026

Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Mon, 03 Aug 2026 16:05:00 -0400

Announced Vertex Agreement to Acquire Crinetics for Total Equity Value of Approximately $10.0 Billion, or Approximately $8.8B Net of Estimated Cash Acquired

PALSONIFY® (Paltusotine) Net Product Revenue of $24.0 Million for Second-Quarter 2026

Form SCHEDULE 13G/A Crinetics Pharmaceutical Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.

Mon, 03 Aug 2026 08:29:00 -0400

si-local-file:///var/storage/secattach/20260803/26854412.html

Form SCHEDULE 13G/A Crinetics Pharmaceutical Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.

Mon, 03 Aug 2026 08:29:00 -0400

si-local-file:///var/storage/secattach/20260803/26854412.html

Form DEFM14A Crinetics Pharmaceutical

Fri, 31 Jul 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260731/26850958.html

Form DEFM14A Crinetics Pharmaceutical

Fri, 31 Jul 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260731/26850958.html

UBS Downgrades Crinetics (CRNX) to Neutral

Tue, 28 Jul 2026 02:38:57 -0400

UBS analyst Ashwani Verma downgraded Crinetics (NASDAQ: CRNX) from Buy to Neutral with a price target of $85.00 (from $55.00).

The analyst comments: “We believe VRTX's (covered by Michael Yee) acquisition of CRNX is likely to proceed, given the limited overlap between the companies' pipelines and mechanisms of action. Under the merger agreement, VRTX will acquire CRNX for $85.00 per share in cash, representing a total equity value of ~$10.0 bn (or ~$8.8 bn net of estimated cash acquired). The transaction is expected to close in 3Q26.

In our view, the transaction premium underscores VRTX's conviction in CRNX's strategic value and the

UBS Downgrades Crinetics (CRNX) to Neutral

Tue, 28 Jul 2026 02:38:57 -0400

UBS analyst Ashwani Verma downgraded Crinetics (NASDAQ: CRNX) from Buy to Neutral with a price target of $85.00 (from $55.00).

In our view, the transaction premium underscores VRTX's conviction in CRNX's strategic value and the

Form PREM14A Crinetics Pharmaceutical For: Jul 21

Tue, 21 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260721/26796066.html

Form PREM14A Crinetics Pharmaceutical For: Jul 21

Tue, 21 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260721/26796066.html

Shareholder Alert: Ademi LLP investigates whether Crinetics Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders

Tue, 21 Jul 2026 07:37:44 -0400

MILWAUKEE, July 21, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Crinetics (Nasdaq: CRNX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Vertex.

Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you.

Crinetics shareholders will receive $85.00 per share in cash, representing a total equity value of approximately $10.0 billion, or $8.8 billion net of estimated cash acquired. Crinetics insiders will

Shareholder Alert: Ademi LLP investigates whether Crinetics Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders

Tue, 21 Jul 2026 07:37:44 -0400

Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you.

Crinetics shareholders will receive $85.00 per share in cash, representing a total equity value of approximately $10.0 billion, or $8.8 billion net of estimated cash acquired. Crinetics insiders will

Form DEFA14A Crinetics Pharmaceutical

Fri, 10 Jul 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260710/26757330.html

Form DEFA14A Crinetics Pharmaceutical

Fri, 10 Jul 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260710/26757330.html

Form 8-K Crinetics Pharmaceutical For: Jul 06

Fri, 10 Jul 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260710/26757306.html

Form 8-K Crinetics Pharmaceutical For: Jul 06

Fri, 10 Jul 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260710/26757306.html